0000876343
false
0000876343
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 10, 2023
Lineage
Cell Therapeutics, Inc.
(Exact
name of registrant as specified in charter)
| California |
|
001-12830 |
|
94-3127919 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2173
Salk Avenue, Suite 200
Carlsbad,
California |
|
92008 |
| (Address of principal executive
offices) |
|
(Zip Code) |
(442)
287-8990
Registrant’s
telephone number, including area code
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common shares |
|
LCTX |
|
NYSE American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
August 10, 2023, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended June 30, 2023,
a copy of which is furnished as Exhibit 99.1.
The
information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any
filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in
such a filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Lineage Cell Therapeutics, Inc. |
| |
|
|
| Date: August 10, 2023 |
By: |
/s/ George
A. Samuel III |
| |
Name: |
George A. Samuel III |
| |
Title: |
General Counsel and Corporate Secretary |
Exhibit
99.1
LINEAGE
CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
| |
● |
Enrollment
Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with GA Secondary to AMD Under Management of
Genentech, a Member of the Roche Group |
| |
● |
FDA
Type B Meeting Response Provides Path for New OPC1 Delivery Device |
| |
● |
Positive
Topline Data Reported from Phase 1 VAC2 Study for the Treatment of NSCLC |
| |
● |
Lineage
Added to Russell 3000® Index |
| |
● |
Established
and Presented 1st Annual Spinal Cord Injury Investor Symposium |
CARLSBAD,
CA – August 10, 2023 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology
company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter
ended June 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.
“The
Lineage team continued to execute across multiple fronts during the second quarter, advancing our clinical and preclinical cell transplant
programs and supporting our valuable alliances,” stated Brian M. Culley, Lineage CEO. “The most important area of attention
was our partnership with Roche and Genentech and continued support for the ongoing Phase 2a clinical study of OpRegen in patients with
GA secondary to AMD, which has been enrolling patients from multiple sites in the U.S. Through presentations at medical and scientific
conferences, we also sought to increase awareness of OpRegen’s potential to provide durable anatomical and functional improvements
to patients with advanced dry AMD. In partnership with CIRM and the Christopher & Dana Reeve Foundation, we created and presented
the 1st Annual Spinal Cord Injury Investor Symposium, which brought together stakeholders to share expertise on spinal cord
injury and reflects the receipt of a new and clarified path we obtained from FDA for an IND amendment for our OPC1 program.
We also reported positive clinical results from a Phase 1 study of VAC2 in non-small cell lung cancer alongside our partner, Cancer Research
UK. Looking ahead, we will continue to focus on making progress across our pipeline while maintaining our rigorous commitment
to disciplined spending. Overall, we believe the use of differentiated allogeneic cell transplants can provide a meaningful impact for
patients and are encouraged by the progress we and others have made in this field.”
Recent
milestones and activities included:
| |
○ |
Continued
execution under our collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing
Phase 2a multi-center clinical study in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD): |
| |
▪ |
Additional sites expected to come online this year
for the Phase 2a study. |
| |
▪ |
Preliminary
evidence of durable anatomical and functional improvements following administration of OpRegen cells from the Phase 1/2a clinical
study was presented at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and other medical and
scientific meetings, including durable improvement observed in one patient with long-term follow-up available (4 years). |
| |
- |
Type
B meeting response from FDA facilitates IND amendment submission for clinical testing of novel OPC1 spinal cord delivery system |
| |
○ |
IND
amendment preparation underway, with plans to submit to FDA in Q4. |
| |
- |
Announced
encouraging topline results from Phase 1 clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC) in partnership
with Cancer Research UK (CRUK) |
| |
○ |
VAC2
appeared to be well tolerated in all treated patients and the adverse events observed were modest and expected from a therapy designed
to generate a robust and durable immune response to tumor antigens. |
| |
○ |
Response
data in these refractory patients was encouraging with five of eight participants demonstrating a best response of immune-related
stable disease and three patients demonstrating immune-related progressive disease. Three of eight treated patients also reached
the 2-year survival endpoint. |
| |
○ |
Two
patients demonstrated durable responses against segments of the applicable tumor antigen and two other patients had transient responses
as assessed via enzyme-linked immunospot (ELISPOT) assays. |
| |
- |
Added
to the broad-market Russell 3000® Index |
| |
○ |
Our
inclusion in the broader index can help to expand investor awareness, increase institutional ownership, and provide additional liquidity
in our stock. |
| |
- |
Established
and presented the 1st Annual Spinal Cord Injury Investor Symposium (SCIIS). |
| |
○ |
The
goals of this collaborative effort included an increase in disease awareness, improving the probability of success in product development,
and supporting clinical trial participation by focusing on topics such as patient-appropriate clinical endpoints. We are grateful
to the sponsors and collaborators for this inaugural event, including CIRM, the Christopher & Dana Reeve Foundation,
the Sanford Stem Cell Institute at the University of California San Diego, and AbbVie. |
Balance
Sheet Highlights
Cash,
cash equivalents, and marketable securities totaled $45.9 million as of June 30, 2023, which is expected to support planned operations
into Q4 2024.
Second
Quarter Operating Results
Revenues:
Lineage’s revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues
for the three months ended June 30, 2023 were $3.2 million, a net decrease of $1.4 million as compared to approximately $4.6 million
for the same period in 2022. The decrease was primarily driven by less collaboration and licensing revenue recognized from deferred revenues
from the Roche Agreement.
Operating
Expenses: Operating expenses are comprised of research and development (“R&D”) expenses and general and administrative
(“G&A”) expenses. Total operating expenses for the three months ended June 30, 2023 were $8.1 million, a decrease of
$0.5 million as compared to $8.6 million for the same period in 2022.
R&D
Expenses: R&D expenses for the three months ended June 30, 2023 were $3.9 million, a net increase of $0.6 million as compared
to $3.3 million for the same period in 2022. The net increase was primarily driven by $0.4 million in higher OpRegen program-related
expenses, and $0.3 million in non-clinical-related expenses to support the OPC1 program.
G&A
Expenses: G&A expenses for the three months ended June 30, 2023 were $4.2 million, a net decrease of approximately $1.1 million
as compared to $5.3 million for the same period in 2022. The decrease was primarily driven by $0.5 million in lower litigation and legal
expenses, and an overall reduction in costs incurred for services by third parties, consulting costs, and stock-based compensation expense.
Loss
from Operations: Loss from operations for the three months ended June 30, 2023 was $5.0 million, an increase of $0.8 million as compared
to $4.2 million for the same period in 2022.
Other
Income/(Expenses), Net: Other income (expenses), net for the three months ended June 30, 2023 reflected other expense, net of ($0.2)
million, compared to other expense, net of ($2.5) million for the same period in 2022. The net change was primarily driven by exchange
rate fluctuations related to Lineage’s international subsidiaries, fair market value changes in marketable equity securities, and
interest income from our marketable debt securities.
Net
Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended June 30, 2023 was $5.2 million, or
$0.03 per share (basic and diluted), compared to a net loss attributable to Lineage of $6.8 million, or $0.04 per share (basic and diluted),
for the same period in 2022.
Conference
Call and Webcast
Interested
parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the
“Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors
section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone
replay will be available through August 17, 2023, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number
1144985.
About
Lineage Cell Therapeutics, Inc.
Lineage
Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s
programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor
cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent
due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to
cancer. Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic
(“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for
the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration
with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development
for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform
for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer;
(iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor
neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please
visit www.lineagecell.com or follow the company on Twitter @LineageCell.
Forward-Looking
Statements
Lineage
cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “design,” “intend,”
“expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,”
“should,” “would,” “contemplate,” “project,” “target,” “tend to,”
or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating
to: the significance of the Phase 2a clinical study of OpRegen and the expansion of the study to additional clinical sites; that our
cash, cash equivalents and marketable securities is sufficient to support our planned operations into the fourth quarter of 2024; plans
and expectations regarding publications and presentations related to our programs, the timing of anticipated regulatory submissions to
the FDA related to our programs, including OPC1, the potential future achievements of our clinical, preclinical and development programs,
the initiation of clinical trials and the availability of clinical data updates related to our programs; plans and expectations regarding
existing collaborations; the effect of the SCIIS, including increasing disease awareness, the probability of success in product development,
and clinical trial participation; the potential effects of being added to the Russel 3000 Index; our ability to broaden awareness of
our mission, programs and accomplishments; and the potential of our cell therapy platform and our ability to provide an meaningful impact
for patients. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s
actual results, performance or achievements to be materially different from future results, performance or achievements expressed or
implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need
to allocate our cash to unexpected events and expenses causing us to use our cash, cash equivalents and marketable securities more quickly
than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success
in subsequent clinical and/or nonclinical studies of that candidate; that OpRegen may never be proven to provide durable anatomical functional
improvements in dry-AMD patients, that competing alternative therapies may adversely impact the commercial potential of OpRegen; that
Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining
regulatory approval for OpRegen in any particular jurisdiction; that the feedback received from the FDA for OPC1 may not enable further
clinical development; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance
with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed
in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon
its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements
are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included
under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent
Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned
not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made,
except as required by law.
Lineage
Cell Therapeutics, Inc. IR
Ioana
C. Hone
(ir@lineagecell.com)
(442)
287-8963
LifeSci
Advisors
Daniel
Ferry
(daniel@lifesciadvisors.com)
(617)
430-7576
Russo
Partners – Media Relations
Nic
Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212)
845-4242
Tables
to follow
LINEAGE
CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(IN
THOUSANDS)
| | |
June 30, 2023 | | |
December 31, | |
| | |
(Unaudited) | | |
2022 | |
| ASSETS | |
| | | |
| | |
| CURRENT ASSETS | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 33,886 | | |
$ | 11,355 | |
| Marketable securities | |
| 12,039 | | |
| 46,520 | |
| Accounts receivable, net | |
| 443 | | |
| 297 | |
| Prepaid expenses and other current assets | |
| 2,123 | | |
| 1,828 | |
| Total current assets | |
| 48,491 | | |
| 60,000 | |
| | |
| | | |
| | |
| NONCURRENT ASSETS | |
| | | |
| | |
| Property and equipment, net | |
| 5,310 | | |
| 5,673 | |
| Deposits and other long-term assets | |
| 588 | | |
| 627 | |
| Goodwill | |
| 10,672 | | |
| 10,672 | |
| Intangible assets, net | |
| 46,627 | | |
| 46,692 | |
| TOTAL ASSETS | |
$ | 111,688 | | |
$ | 123,664 | |
| | |
| | | |
| | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| CURRENT LIABILITIES | |
| | | |
| | |
| Accounts payable and accrued liabilities | |
$ | 4,685 | | |
$ | 8,608 | |
| Lease liabilities, current portion | |
| 933 | | |
| 916 | |
| Financing lease, current portion | |
| 54 | | |
| 36 | |
| Deferred revenues | |
| 10,379 | | |
| 9,421 | |
| Other current liabilities | |
| 1 | | |
| - | |
| Total current liabilities | |
| 16,052 | | |
| 18,981 | |
| | |
| | | |
| | |
| LONG-TERM LIABILITIES | |
| | | |
| | |
| Deferred tax liability | |
| 273 | | |
| 2,076 | |
| Deferred revenues, net of current portion | |
| 21,688 | | |
| 27,725 | |
| Lease liability, net of current portion | |
| 2,304 | | |
| 2,860 | |
| Financing lease, net of current portion | |
| 113 | | |
| 84 | |
| Other long-term liabilities | |
| - | | |
| 2 | |
| TOTAL LIABILITIES | |
| 40,430 | | |
| 51,728 | |
| | |
| | | |
| | |
| SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Preferred shares, no par value, authorized 2,000 shares; none issued and
outstanding as of June 30, 2023 and December 31, 2022 | |
| - | | |
| - | |
Common shares, no par value, 250,000 shares authorized; 174,439 and
170,093 shares issued and outstanding as of June 30, 2023 and
December 31, 2022, respectively | |
| 448,249 | | |
| 440,280 | |
| Accumulated other comprehensive loss | |
| (2,611 | ) | |
| (3,571 | ) |
| Accumulated deficit | |
| (372,971 | ) | |
| (363,370 | ) |
| Lineage Cell Therapeutics, Inc. shareholders’ equity | |
| 72,667 | | |
| 73,339 | |
| Noncontrolling deficit | |
| (1,409 | ) | |
| (1,403 | ) |
| Total shareholders’ equity | |
| 71,258 | | |
| 71,936 | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 111,688 | | |
$ | 123,664 | |
LINEAGE
CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN
THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
| | |
Three Months ended June 30, | | |
Six Months ended June 30, | |
| | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| REVENUES: | |
| | | |
| | | |
| | | |
| | |
| Collaboration revenues | |
$ | 2,871 | | |
$ | 4,148 | | |
$ | 4,992 | | |
$ | 9,013 | |
| Royalties and license fees | |
| 354 | | |
| 405 | | |
| 619 | | |
| 777 | |
| Total revenues | |
| 3,225 | | |
| 4,553 | | |
| 5,611 | | |
| 9,790 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost of sales | |
| (127 | ) | |
| (215 | ) | |
| (246 | ) | |
| (391 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Gross profit | |
| 3,098 | | |
| 4,338 | | |
| 5,365 | | |
| 9,399 | |
| | |
| | | |
| | | |
| | | |
| | |
| OPERATING EXPENSES: | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 3,873 | | |
| 3,302 | | |
| 8,058 | | |
| 6,290 | |
| General and administrative | |
| 4,249 | | |
| 5,270 | | |
| 8,973 | | |
| 13,739 | |
| Total operating expenses | |
| 8,122 | | |
| 8,572 | | |
| 17,031 | | |
| 20,029 | |
| Loss from operations | |
| (5,024 | ) | |
| (4,234 | ) | |
| (11,666 | ) | |
| (10,630 | ) |
| OTHER INCOME (EXPENSES): | |
| | | |
| | | |
| | | |
| | |
| Interest income, net | |
| 382 | | |
| 51 | | |
| 792 | | |
| 51 | |
| Unrealized loss on marketable equity securities, net | |
| (150 | ) | |
| (709 | ) | |
| (110 | ) | |
| (1,444 | ) |
| Gain on revaluation of warrant liability | |
| - | | |
| 2 | | |
| 1 | | |
| 223 | |
| Other expenses, net | |
| (411 | ) | |
| (1,892 | ) | |
| (427 | ) | |
| (2,075 | ) |
| Total other income (expenses), net | |
| (179 | ) | |
| (2,548 | ) | |
| 256 | | |
| (3,245 | ) |
| LOSS BEFORE INCOME TAXES | |
| (5,203 | ) | |
| (6,782 | ) | |
| (11,410 | ) | |
| (13,875 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Deferred income tax benefit | |
| - | | |
| - | | |
| 1,803 | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| NET LOSS | |
| (5,203 | ) | |
| (6,782 | ) | |
| (9,607 | ) | |
| (13,875 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net (income) loss attributable to noncontrolling interest | |
| (26 | ) | |
| 19 | | |
| 6 | | |
| 25 | |
| | |
| | | |
| | | |
| | | |
| | |
| NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC. | |
$ | (5,229 | ) | |
$ | (6,763 | ) | |
$ | (9,601 | ) | |
$ | (13,850 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| NET LOSS PER COMMON SHARE: | |
| | | |
| | | |
| | | |
| | |
| BASIC | |
$ | (0.03 | ) | |
$ | (0.04 | ) | |
$ | (0.06 | ) | |
$ | (0.08 | ) |
| DILUTED | |
$ | (0.03 | ) | |
$ | (0.04 | ) | |
$ | (0.06 | ) | |
$ | (0.08 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | |
| | | |
| | | |
| | | |
| | |
| BASIC | |
| 170,592 | | |
| 169,731 | | |
| 170,361 | | |
| 169,689 | |
| DILUTED | |
| 170,592 | | |
| 169,731 | | |
| 170,361 | | |
| 169,689 | |
LINEAGE
CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN
THOUSANDS)
(UNAUDITED)
| | |
Six Months ended June 30, | |
| | |
2023 | | |
2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
| Net loss attributable to Lineage Cell Therapeutics, Inc. | |
$ | (9,601 | ) | |
$ | (13,850 | ) |
| Net loss allocable to noncontrolling interest | |
| (6 | ) | |
| (25 | ) |
| Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash (used in) provided by operating activities: | |
| | | |
| | |
| Accretion of income on marketable debt securities | |
| (516 | ) | |
| - | |
| Unrealized loss on marketable equity securities, net | |
| 110 | | |
| 1,444 | |
| Depreciation expense, including amortization of leasehold improvements | |
| 276 | | |
| 296 | |
| Change in right-of-use assets and liabilities | |
| 81 | | |
| (7 | ) |
| Amortization of intangible assets | |
| 65 | | |
| 65 | |
| Stock-based compensation | |
| 2,311 | | |
| 2,341 | |
| Gain on revaluation of warrant liability | |
| (1 | ) | |
| (223 | ) |
| Deferred income tax benefit | |
| (1,803 | ) | |
| - | |
| Foreign currency remeasurement and other gain | |
| 1,012 | | |
| 2,331 | |
| Changes in operating assets and liabilities: | |
| | | |
| | |
| Accounts receivable, net | |
| (147 | ) | |
| 50,111 | |
| Prepaid expenses and other current assets | |
| (270 | ) | |
| 594 | |
| Accounts payable and accrued liabilities | |
| (3,941 | ) | |
| (19,230 | ) |
| Deferred revenue and other liabilities | |
| (5,080 | ) | |
| (9,005 | ) |
| Net cash (used in) provided by operating activities | |
| (17,510 | ) | |
| 14,842 | |
| | |
| | | |
| | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
| Purchases of marketable debt securities | |
| (12,635 | ) | |
| - | |
| Maturities of marketable debt securities | |
| 47,664 | | |
| - | |
| Purchase of equipment and other assets, net | |
| (444 | ) | |
| (143 | ) |
| Net cash provided by (used in) investing activities | |
| 34,585 | | |
| (143 | ) |
| | |
| | | |
| | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
| Proceeds from employee options exercised | |
| 80 | | |
| 388 | |
| Common shares received and retired for employee taxes paid | |
| (37 | ) | |
| (17 | ) |
| Proceeds from exercise of subsidiary warrants, net | |
| - | | |
| 99 | |
| Proceeds from sale of common shares | |
| 5,789 | | |
| 148 | |
| Payments for offering costs | |
| (174 | ) | |
| (57 | ) |
| Repayment of financing lease liability | |
| (29 | ) | |
| (15 | ) |
| Net cash provided by financing activities | |
| 5,629 | | |
| 546 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | |
| (192 | ) | |
| (161 | ) |
| NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |
| 22,512 | | |
| 15,084 | |
| | |
| | | |
| | |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | |
| | | |
| | |
| At beginning of the period | |
| 11,936 | | |
| 56,277 | |
| At end of the period | |
$ | 34,448 | | |
$ | 71,361 | |
v3.23.2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Jan 2024 to Jan 2025
